## **Tobias Gutting**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2760834/publications.pdf

Version: 2024-02-01

1040056 1125743 14 216 9 13 citations h-index g-index papers 15 15 15 413 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Nivolumab plus ipilimumab in second-line combination therapy for older patients with esophageal squamous cell cancer (AIO-STO-0117 trial) Journal of Clinical Oncology, 2022, 40, 303-303.	1.6	1
2	PPARÎ <sup>3</sup> induces PD-L1 expression in MSS+ colorectal cancer cells. Oncolmmunology, 2021, 10, 1906500.	4.6	15
3	Myotubularin-related protein 7 activates peroxisome proliferator-activated receptor-gamma. Oncogenesis, 2020, 9, 59.	4.9	6
4	Docking protein-1 promotes inflammatory macrophage signaling in gastric cancer. Oncolmmunology, 2019, 8, e1649961.	4.6	14
5	Detection of mutational patterns in cellâ€free DNA of colorectal cancer by custom amplicon sequencing. Molecular Oncology, 2019, 13, 1669-1683.	4.6	8
6	A multicenter open-label phase II trial to evaluate nivolumab and ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer (RAMONA). BMC Cancer, 2019, 19, 231.	2.6	19
7	Spatial Distribution of Endogenous Tissue Protease Activity in Gastric Carcinoma Mapped by MALDI Mass Spectrometry Imaging. Molecular and Cellular Proteomics, 2019, 18, 151-161.	3.8	26
8	Checkpoints and beyond – Immunotherapy in colorectal cancer. Seminars in Cancer Biology, 2019, 55, 78-89.	9.6	38
9	Complete Remission of Metastatic HER2+ Oesophagogastric Junctional Adenocarcinoma under long-term Trastuzumab Treatment. Journal of Gastrointestinal and Liver Diseases, 2019, 28, 503-507.	0.9	2
10	PPAR $\hat{i}^3$ -activation increases intestinal M1 macrophages and mitigates formation of serrated adenomas in mutant <i>KRAS</i> mice. Oncolmmunology, 2018, 7, e1423168.	4.6	12
11	A multicenter phase 4 geriatric assessment directed trial to evaluate gemcitabine $+/\hat{a}^{\gamma}$ nab-paclitaxel in elderly pancreatic cancer patients (GrantPax). BMC Cancer, 2018, 18, 747.	2.6	24
12	Epigenetic silencing of tumor suppressor candidate 3 confers adverse prognosis in early colorectal cancer. Oncotarget, 2017, 8, 84714-84728.	1.8	5
13	Subcellular compartmentalization of docking protein-1 contributes to progression in colorectal cancer. EBioMedicine, 2016, 8, 159-172.	6.1	15
14	Myotubularin-related protein 7 inhibits insulin signaling in colorectal cancer. Oncotarget, 2016, 7, 50490-50506.	1.8	21